GOVERNMENT OF NCT of DELHI DEPARTMENT OF HEALTH & FAMILY WELFARE IRDER F No. PAISSSHFW/2021/Tocilizomab/CD-112648651/ 5°‘ fof Dated :13.5.2021 237-246 In order to streamline and systematize the distribution of Tocilizumab injections to prevent the indiscriminate use of this injection and to establish a transparent, efficient and time-bound system of distribution of this drug to the needy and hospitalized COVID- 19 patients on clinically approved evidence-based grounds and ethical principle of distributive justice across Delhi, the competent authority has approved the constitution of a 3 member ‘Technical Expert Committee (TEC) as follows: 1) Dr. Paeeeraenenee). as Chairman. esia Branch, MAMC) re prescribed to approve the distribution/supply of pitals (Govt and Private) only for the treatment of lospitals requiring Injection Tocilizumab for ply to the Technical Experts Committee. \nnexure-A) to be sent to the TEC through cation without filled proforma or incomplete meetings can be held on a Il be evidence based clinically distributive justice and Scanned with CamScannervi. On recomm i sitiGitoed peepee Of the TEC, the olo DGHS shall issue the drug to the f CF, aha Baan, Government Hospital/institution concerned or the e / Concerned (in this ae fepresentative of the Private Hospital basis) as the case may be vii. DGHS and all the CFAsiStockists will ensure the issuance of drug on same day nt and Private Hospital concemed. Respectively, All relevant records ‘by o/oDGHS. v/Private hospital will submit report regarding usage of drug for ponsibility of the Hospital Administration of the ensure appropriate use of prescription medicine, tion with health authorities and to keep proper ment Agencies on special (pz a Ash Raj Kumar Spl. Secretary, (H&FW) Scanned with CamScannerAnnexure- A GOVERNMENT OF NCT of DELHI DEPARTMENT OF HEALTH & FAMILY WELFARE ni 2 nly @ multidisciplinary team or 3 members team consisting of physician volved in COVID patient care (to be signed by at least two) can recommend ‘the use of Tocilizumab/Immunomodulator therapy. followil meters have to be considered and recorded Condition Coexistent infection other than COVID-19 PaO2/FiO2> 300 mm Hg; chronic lucocorticoid use H/o another ILG inhibitor in resent admission. | H/O severe allergic reactions to onoclonal antibodies <500 per MLiplatelets < ‘diverticulitis, IBD, or iptomatic inal tract condition that canned with CamScannerPresently admitted in (ODIMM/Year) is found to be an eligible for Tocilizumab Scanned with CamScanner